Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.70
-0.9800-1.45%
Post-market: 66.41-0.2900-0.43%19:30 EDT
Volume:1.59M
Turnover:106.77M
Market Cap:12.89B
PE:176.00
High:68.34
Open:67.55
Low:66.52
Close:67.68
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.90
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.04
PE(LYR):37.06

Loading ...

Biomarin Pharmaceutical Q1 Net Income USD 106 Million

THOMSON REUTERS
·
May 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

How Investors Are Reacting To BioMarin (BMRN) VOXZOGO Data Showing Benefits Beyond Height in Achondroplasia

Simply Wall St.
·
May 04

BioMarin announces new research from studies of Voxzogo

TIPRANKS
·
May 04

BioMarin says VOXZOGO long-term trials improve arm span, maintain bone density in achondroplasia

Reuters
·
May 03

Biomarin Presents New Data on the Effect of Long-Term Treatment With Voxzogo® (Vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

THOMSON REUTERS
·
May 03

BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a share - Earnings Preview

Reuters
·
May 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

MT Newswires Live
·
Apr 27

BioMarin completes acquisition of Amicus Therapeutics

TIPRANKS
·
Apr 27

BioMarin completes Amicus acquisition for USD 14.5 per share, valuing deal at USD 4.8 billion

Reuters
·
Apr 27

Biomarin Completes Acquisition of Amicus Therapeutics

THOMSON REUTERS
·
Apr 27

BioMarin to host first-quarter results conference call and webcast

Reuters
·
Apr 27

Morgan Stanley Resumes BioMarin Pharmaceutical at Overweight With $120 Price Target

MT Newswires Live
·
Apr 27

BioMarin resumed with an Overweight at Morgan Stanley

TIPRANKS
·
Apr 27

Piper Sandler Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Apr 24

BioMarin wins French FDI clearance for Amicus merger, closing expected April 27

Reuters
·
Apr 24

Biomarin Pharmaceutical Inc - France Grants Fdi Clearance for Biomarin-Amicus Merger on April 23, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 24

BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial

TIPRANKS
·
Apr 24

BRIEF-Biomarin Announces Board Leadership Transition

Reuters
·
Apr 22